Officials limit an antibody therapy, saying it’s ineffective against BA.2 variant of Omicron

U.S. health officials on Friday stopped the further deployment of the Covid-19 treatment sotrovimab to places where the BA.2 coronavirus variant is now causing the majority of infections, given laboratory studies showing the treatment likely doesn’t work against the variant.

States in New England, as well as New York, New Jersey, Puerto Rico, and the Virgin Islands, will no longer receive shipments of the monoclonal antibody therapy made by Vir Biotechnology and GSK, officials said.